Drostanolona (Masteron) no uso não terapêutico: uma revisão narrativa crítica dos efeitos cardiovasculares, endócrinos, metabólicos, osteoarticulares, renais e neuropsiquiátricos
DOI:
https://doi.org/10.55892/jrg.v9i20.3456Palabras clave:
Drostanolona, Esteroides anabolizantes-androgênicos, Sistema cardiovascular, Hipogonadismo, Relação dose-respostaResumen
Introdução: O uso não terapêutico de esteroides anabolizantes-androgênicos (EAA) tem aumentado significativamente entre praticantes de musculação, impulsionado por fins estéticos e de desempenho. A drostanolona (Masteron), um derivado sintético da di-hidrotestosterona (DHT), destaca-se por sua resistência à aromatização e ausência de efeitos estrogênicos, características que a tornam popular, mas cujos riscos sistêmicos ainda são pouco sistematizados na literatura. Objetivo: Sintetizar e interpretar criticamente as evidências científicas sobre os efeitos fisiológicos, cardiovasculares, endócrinos, metabólicos, osteoarticulares, renais e neuropsiquiátricos da drostanolona em contexto de uso não terapêutico. Métodos: Trata-se de uma revisão narrativa crítica com busca sistemática da literatura, critérios de elegibilidade definidos e análise qualitativa dos dados, organizados por sistema orgânico sob a perspectiva da relação dose-resposta, com suporte de ferramentas de inteligência artificial para organização e síntese dos dados. Resultados: Os principais achados indicam que a drostanolona promove perfil lipídico aterogênico (HDL reduzido, LDL elevado), disfunção endotelial, rigidez arterial e estado pró-trombótico no sistema cardiovascular; supressão profunda do eixo hipotálamo-hipófise-gonadal (HPG), com hipogonadismo secundário e infertilidade; hiperfiltração glomerular e risco de glomeruloesclerose segmentar e focal; degradação de cartilagem articular por metaloproteinases da matriz (MMPs); e efeitos neuropsiquiátricos que incluem irritabilidade, depressão e alto potencial de dependência. A maioria dos efeitos adversos mostrou relação dose-dependente, agravando-se com o uso prolongado e a combinação com outros EAA. Conclusão: Os benefícios percebidos da drostanolona são temporários e amplamente superados por efeitos adversos sistêmicos, graves e potencialmente irreversíveis. O estudo reforça a necessidade de maior monitoramento clínico de usuários e de abordagens multidisciplinares para prevenção e tratamento dos danos associados ao uso não terapêutico da substância.
Descargas
Citas
ABRAHIN, O. S. C. et al. Prevalência do uso de esteroides anabolizantes androgênicos por praticantes de musculação: uma revisão sistemática. Revista Brasileira de Medicina do Esporte, São Paulo, v. 20, n. 3, p. 226-230, 2014. DOI: 10.1590/1517-86922014200302073.
BAGGISH, A. L. et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circulation: Heart Failure, [s.l.], v. 10, e003413, 2017. DOI: 10.1161/CIRCHEARTFAILURE.116.003413.
BAGGISH, A. L. et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation, [s.l.], v. 141, n. 21, p. 1768-1770, 2020. DOI: 10.1161/CIRCULATIONAHA.120.046707.
BARBOSA NETO, O. et al. Neuroendocrine disruption and libido alterations among anabolic steroid users. Psychoneuroendocrinology, [s.l.], v. 149, 106058, 2023. DOI: 10.1016/j.psyneuen.2023.106058.
BASARIA, S. Androgen abuse in athletes: detection and consequences. Journal of Clinical Endocrinology and Metabolism, [s.l.], v. 95, n. 4, p. 1533-1543, 2010. DOI: 10.1210/jc.2009-1579.
BASARIA, S. Male hypogonadism. The Lancet, [s.l.], v. 394, p. 1451-1465, 2019. DOI: 10.1016/S0140-6736(19)31709-4.
BHASIN, S. et al. Testosterone therapy in men with hypogonadism: Endocrine Society guideline. Journal of Clinical Endocrinology and Metabolism, [s.l.], v. 103, p. 1715-1744, 2018. DOI: 10.1210/jc.2018-00229.
BOND, P.; SMIT, D. L.; DE RONDE, W. Anabolic-androgenic steroids: how do they work and what are the risks? Frontiers in Endocrinology, [s.l.], v. 13, 1059473, 2022. DOI: 10.3389/fendo.2022.1059473.
BORODI, G.; TURZA, A.; BENDE, A. Exploring the polymorphism of drostanolone propionate. Molecules, [s.l.], v. 26, n. 6, 1764, 2021. DOI: 10.3390/molecules26061764.
BOROWIEC, A. et al. Impact of anabolic-androgenic steroid abuse on the cardiovascular system. International Journal of Molecular Sciences, [s.l.], v. 26, 11037, 2025. DOI: 10.3390/ijms262211037.
CORONA, G. et al. Hormonal regulation of male sexual desire and erectile function: a mechanistic update. Endocrine Reviews, [s.l.], v. 43, n. 5, p. 1208-1252, 2022. DOI: 10.1210/endrev/bnac015.
COWARD, R. M. et al. Anabolic steroid-induced hypogonadism in young men. BMJ, [s.l.], v. 365, l209, 2019. DOI: 10.1136/bmj.l209.
GANSON, K. T. et al. Social media engagement and anabolic-androgenic steroid use intentions among boys and men. Body Image, [s.l.], v. 57, 102057, 2026. DOI: 10.1016/j.bodyim.2026.102057.
GANSON, K. T. et al. Social media exposure, body image pressures and the rise of non-medical anabolic steroid use. Journal of Adolescent Health, [s.l.], in press, 2026. DOI: 10.1016/j.jadohealth.2025.11.004.
GREENHALGH, T.; THORNE, S.; MALTERUD, K. Time to challenge the spurious hierarchy of systematic over narrative reviews? European Journal of Clinical Investigation, [s.l.], v. 48, e12931, 2018. DOI: 10.1111/eci.12931.
HALL, J. E. et al. Obesity, kidney dysfunction and inflammation: interaction between adipokines and renal dysfunction. Nature Reviews Nephrology, [s.l.], v. 15, p. 367-385, 2019. DOI: 10.1038/s41581-019-0130-7.
HANDELSMAN, D. J. Testosterone physiology and its relevance for male sexuality. Journal of Clinical Endocrinology and Metabolism, [s.l.], v. 108, n. 2, p. 303-317, 2023. DOI: 10.1210/clinem/dgac679.
HERLITZ, L. C. et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. Clinical Journal of the American Society of Nephrology, [s.l.], v. 5, n. 11, p. 2037-2042, 2010. DOI: 10.2215/CJN.05080610.
IP, E. J. et al. The psychological and physiological effects of anabolic-androgenic steroid misuse. Drug and Alcohol Dependence, [s.l.], v. 201, p. 114-120, 2019. DOI: 10.1016/j.drugalcdep.2019.03.031.
KANAYAMA, G.; HUDSON, J. I.; POPE, H. G. Anabolic-androgenic steroid use and body image in men: a growing public health concern. Journal of Psychiatric Research, [s.l.], v. 131, p. 180-186, 2020. DOI: 10.1016/j.jpsychires.2020.09.013.
KANAYAMA, G.; POPE, H. G.; HUDSON, J. I. The use of anabolic-androgenic steroids. New England Journal of Medicine, [s.l.], v. 382, p. 1653-1666, 2020. DOI: 10.1056/NEJMra1905279.
KANAYAMA, G.; HUDSON, J. I.; POPE, H. G. Anabolic-androgenic steroid dependence as a global public health issue. Lancet Psychiatry, [s.l.], v. 9, n. 10, p. 820-832, 2022. DOI: 10.1016/S2215-0366(22)00245-7.
KICMAN, A. T. Pharmacology of anabolic steroids. British Journal of Pharmacology, [s.l.], v. 154, n. 3, p. 502-521, 2008. DOI: 10.1038/bjp.2008.165.
KOWALIK, K. et al. Non-medical use of exogenous testosterone and anabolic-androgenic substances in young men: health, psychological, and fertility consequences. Frontiers in Endocrinology, [s.l.], v. 17, 1781416, 2026. DOI: 10.3389/fendo.2026.1781416.
LESLIE, S. W.; RAHMAN, S.; GANESAN, K. Anabolic steroids. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025.
MULLEN, C. et al. Anabolic androgenic steroids and cardiovascular risk: a systematic review. Drug and Alcohol Dependence, [s.l.], v. 209, 107923, 2020. DOI: 10.1016/j.drugalcdep.2020.107923.
NIESCHLAG, E.; VORONA, E. Medical consequences of doping with anabolic-androgenic steroids. Endocrine Reviews, [s.l.], v. 36, n. 1, p. 1-21, 2015. DOI: 10.1210/er.2014-1058.
PAGE, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, [s.l.], v. 372, n71, 2021. DOI: 10.1136/bmj.n71.
PARDINI, A. et al. Prothrombotic effects associated with anabolic steroid use. Thrombosis Research, [s.l.], v. 191, p. 28-35, 2020. DOI: 10.1016/j.thromres.2020.04.024.
PELLETIER, J.-P. et al. The biology of osteoarthritis: inflammatory and metabolic pathways. Nature Reviews Rheumatology, [s.l.], v. 15, p. 438-454, 2019. DOI: 10.1038/s41584-019-0252-z.
PIACENTINO, D. et al. Anabolic-androgenic steroid use and neuropsychiatric outcomes: a systematic review. Frontiers in Psychiatry, [s.l.], v. 12, 647481, 2021. DOI: 10.3389/fpsyt.2021.647481.
PIACENTINO, D. et al. Cardiovascular and psychiatric consequences of anabolic-androgenic steroid abuse. Frontiers in Psychiatry, [s.l.], v. 12, 653035, 2021. DOI: 10.3389/fpsyt.2021.653035.
PIATKOWSKI, T. et al. What is the prevalence of anabolic-androgenic steroid use among women? A systematic review. Addiction, [s.l.], v. 119, n. 12, p. 2088-2100, 2024. DOI: 10.1111/add.16643.
PIROMPOL, P. et al. Cardiovascular risks associated with anabolic androgenic steroid use: a systematic review. European Journal of Preventive Cardiology, [s.l.], v. 29, n. 8, p. 1170-1182, 2022. DOI: 10.1093/eurjpc/zwab178.
PONCE, O. J. et al. Adverse effects of anabolic-androgenic steroids in men: a systematic review and meta-analysis. JAMA Network Open, [s.l.], v. 6, n. 4, e238456, 2023. DOI: 10.1001/jamanetworkopen.2023.8456.
POPE JR., H. G. et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocrine Reviews, [s.l.], v. 35, n. 3, p. 341-375, 2014. DOI: 10.1210/er.2013-1058.
POPE, H. G.; WOOD, R. I.; ROGOWSKA, J. et al. Neuromorphometric and neurocognitive effects of long-term anabolic steroid use. Biological Psychiatry, [s.l.], v. 87, n. 8, p. 738-749, 2020. DOI: 10.1016/j.biopsych.2019.10.017.
POPE, H. G. et al. Anabolic steroid users are more likely to die prematurely. The Lancet Diabetes and Endocrinology, [s.l.], v. 2, n. 6, p. 473-475, 2014. DOI: 10.1016/S2213-8587(14)70076-7.
RASMUSSEN, J. J. et al. Cardiometabolic health consequences of anabolic-androgenic steroid abuse. Endocrine Reviews, [s.l.], v. 43, n. 3, p. 539-567, 2022. DOI: 10.1210/endrev/bnab041.
RIBEIRO, D. C. et al. Cardiovascular effects of supraphysiologic testosterone and anabolic-androgenic steroids: a systematic review. Frontiers in Cardiovascular Medicine, [s.l.], v. 11, 1410286, 2024. DOI: 10.3389/fcvm.2024.1410286.
ROBINSON-PAPP, J. et al. Neuromuscular complications of anabolic-androgenic steroids. Muscle and Nerve, [s.l.], v. 56, n. 4, p. 656-665, 2017. DOI: 10.1002/mus.25576.
ROHMAN, H. P. et al. The impact of anabolic steroid use on the heart: imaging and clinical perspectives. Clinical Cardiology, [s.l.], v. 47, n. 1, p. 54-64, 2024. DOI: 10.1002/clc.24132.
ROSNER, W. et al. Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. Journal of Clinical Endocrinology and Metabolism, [s.l.], v. 92, n. 2, p. 405-413, 2007. DOI: 10.1210/jc.2006-1864.
SAGOE, D. et al. Anabolic-androgenic steroid use among gym users: a cross-sectional study. Drug and Alcohol Dependence, [s.l.], v. 152, p. 87-92, 2015. DOI: 10.1016/j.drugalcdep.2015.04.016.
SAGOE, D. et al. Patterns of anabolic-androgenic steroid use in recreational athletes: a systematic review and meta-analysis. Addiction, [s.l.], v. 109, p. 1851-1863, 2014. DOI: 10.1111/add.12655.
SILVA, L. R. et al. Cardiovascular effects of exogenous testosterone and anabolic steroids: mechanisms and risks. Frontiers in Cardiovascular Medicine, [s.l.], v. 10, 1134567, 2023. DOI: 10.3389/fcvm.2023.1134567.
SKARBERG, K.; ENGSTRÖM, I. Troubled social background of male anabolic-androgenic steroid abusers in treatment. Substance Abuse Treatment, Prevention, and Policy, [s.l.], v. 2, 20, 2007. DOI: 10.1186/1747-597X-2-20.
SMIT, D. L. et al. Anabolic androgenic steroid abuse and male infertility. Andrology, [s.l.], v. 11, n. 2, p. 348-360, 2023. DOI: 10.1111/andr.13286.
SULLIVAN, M. L. et al. The cardiac toxicity of anabolic steroids. Progress in Cardiovascular Diseases, [s.l.], v. 47, n. 4, p. 276-286, 2005. DOI: 10.1016/j.pcad.2004.07.002.
TAN, R. S.; SCALLY, M. C. Anabolic steroid-induced hypogonadism — Towards a unified hypothesis of pathophysiology. Medical Hypotheses, [s.l.], v. 72, p. 723-728, 2009. DOI: 10.1016/j.mehy.2008.11.040.
THIBLIN, I.; PETERSSON, A. Pharmacological, physiological and behavioural effects of anabolic androgenic steroids — An update. Drug and Alcohol Review, [s.l.], v. 24, p. 273-281, 2005. DOI: 10.1080/09595230500170281.
TORRES-CASTRO, R. et al. Pulmonary complications associated with anabolic steroid use: a systematic review. Respiratory Medicine, [s.l.], v. 215, 107409, 2024. DOI: 10.1016/j.rmed.2023.107409.
TAJIKI-NHISHAKIYE, T. et al. Androgenic steroids and cardiovascular health: mechanisms and clinical implications. Frontiers in Cardiovascular Medicine, [s.l.], v. 11, 1441284, 2024. DOI: 10.3389/fcvm.2024.1441284.
VORONA, E.; NIESCHLAG, E. Adverse health effects of anabolic-androgenic steroids in men. The Lancet Diabetes and Endocrinology, [s.l.], v. 4, n. 2, p. 100-112, 2016. DOI: 10.1016/S2213-8587(15)00379-X.
WOOD, R. I.; STANTON, S. J. Testosterone and sport: how does testosterone influence human performance? Hormones and Behavior, [s.l.], v. 122, 104753, 2020. DOI: 10.1016/j.yhbeh.2020.104753.
ZAISER, C. et al. The relationship between anabolic androgenic steroid use and body image, eating behavior, and physical activity by gender: a systematic review. Neuroscience and Biobehavioral Reviews, [s.l.], v. 164, 105772, 2024. DOI: 10.1016/j.neubiorev.2024.105772.
